[go: up one dir, main page]

CY1112134T1 - Φαρμακευτικες συνθεσεις που περιεχουν ανταγωνιστες βραδυκινινης και υαλουρονικο οξυ και χρησεις αυτων - Google Patents

Φαρμακευτικες συνθεσεις που περιεχουν ανταγωνιστες βραδυκινινης και υαλουρονικο οξυ και χρησεις αυτων

Info

Publication number
CY1112134T1
CY1112134T1 CY20111101177T CY111101177T CY1112134T1 CY 1112134 T1 CY1112134 T1 CY 1112134T1 CY 20111101177 T CY20111101177 T CY 20111101177T CY 111101177 T CY111101177 T CY 111101177T CY 1112134 T1 CY1112134 T1 CY 1112134T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
compositions containing
bradykin
acid competitors
haluronic acid
Prior art date
Application number
CY20111101177T
Other languages
English (en)
Inventor
Carlo Alberto Maggi
Sandro Giuliani
Laura Quartara
Original Assignee
Istituto Luso Farmaco D'italia S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Luso Farmaco D'italia S.P.A. filed Critical Istituto Luso Farmaco D'italia S.P.A.
Publication of CY1112134T1 publication Critical patent/CY1112134T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Αποκαλυπτόμενες είναι φαρμακευτικές συνθέσεις που περιέχουν, ως τα δραστικά συστατικά, μίγμα πολυμερούς υαλουρονικού οξέος με ανταγωνιστή υποδοχέα Β2 βραδυκινίνης. Οι εν λόγω συνθέσεις έχουν αποδειχθεί ειδικά αποτελεσματικές στη θεραπεία εκφυλιστικών ασθενειών συνδέσμου, όπως οστεοαρθρίτιδας, χρησιμοποιώντας ενδο-αρθρικές ενέσεις.
CY20111101177T 2007-11-23 2011-11-30 Φαρμακευτικες συνθεσεις που περιεχουν ανταγωνιστες βραδυκινινης και υαλουρονικο οξυ και χρησεις αυτων CY1112134T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002225A ITMI20072225A1 (it) 2007-11-23 2007-11-23 "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso"
EP08853047A EP2222275B1 (en) 2007-11-23 2008-11-10 Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof

Publications (1)

Publication Number Publication Date
CY1112134T1 true CY1112134T1 (el) 2015-11-04

Family

ID=40314753

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101177T CY1112134T1 (el) 2007-11-23 2011-11-30 Φαρμακευτικες συνθεσεις που περιεχουν ανταγωνιστες βραδυκινινης και υαλουρονικο οξυ και χρησεις αυτων

Country Status (40)

Country Link
US (1) US9101627B2 (el)
EP (1) EP2222275B1 (el)
JP (1) JP5383695B2 (el)
KR (1) KR101585868B1 (el)
CN (1) CN101868225B (el)
AP (1) AP2628A (el)
AR (1) AR069407A1 (el)
AT (1) ATE529096T1 (el)
AU (1) AU2008328311B2 (el)
BR (1) BRPI0820402A2 (el)
CA (1) CA2706398C (el)
CL (1) CL2008003475A1 (el)
CO (1) CO6270301A2 (el)
CR (1) CR11457A (el)
CY (1) CY1112134T1 (el)
DK (1) DK2222275T3 (el)
EA (1) EA017626B1 (el)
EC (1) ECSP10010153A (el)
ES (1) ES2374861T3 (el)
GE (1) GEP20125602B (el)
HN (1) HN2010001037A (el)
HR (1) HRP20110904T1 (el)
IL (1) IL205860A (el)
IT (1) ITMI20072225A1 (el)
MA (1) MA31913B1 (el)
MX (1) MX2010005484A (el)
MY (1) MY148685A (el)
NI (1) NI201000087A (el)
NZ (1) NZ585514A (el)
PA (1) PA8804801A1 (el)
PE (1) PE20091422A1 (el)
PL (1) PL2222275T3 (el)
PT (1) PT2222275E (el)
RS (1) RS52045B (el)
SI (1) SI2222275T1 (el)
TN (1) TN2010000215A1 (el)
TW (1) TWI448292B (el)
UA (1) UA97867C2 (el)
WO (1) WO2009065507A2 (el)
ZA (1) ZA201003586B (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO131947A2 (ro) * 2014-05-30 2017-06-30 Nataliia Mykolaivna Derkach Soluţie stabilizată bazată pe substanţe active, şi metodă de preparare a soluţiei stabilizate de substanţe active
WO2016104705A1 (ja) * 2014-12-26 2016-06-30 生化学工業株式会社 眼の自覚症状を改善する剤および方法
US12371683B2 (en) 2018-07-25 2025-07-29 Alteogen Inc. Hyaluronidase variants and pharmaceutical composition comprising the same
US11401303B2 (en) * 2020-06-15 2022-08-02 Taian City Qihang Biotechnology Co. Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof
AU2021320569B2 (en) 2020-08-07 2024-10-03 Alteogen, Inc Method for producing recombinant hyaluronidase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635489B2 (en) * 2001-05-18 2009-12-22 Leneau Holdings, Llc Ingestion of hyaluronic acid for improved joint health
ITMI20021247A1 (it) * 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) * 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"

Also Published As

Publication number Publication date
NI201000087A (es) 2011-07-18
HN2010001037A (es) 2012-12-10
PT2222275E (pt) 2012-01-16
EA201000678A1 (ru) 2010-12-30
IL205860A (en) 2013-01-31
WO2009065507A2 (en) 2009-05-28
EP2222275A2 (en) 2010-09-01
AU2008328311B2 (en) 2013-02-28
MY148685A (en) 2013-05-31
AR069407A1 (es) 2010-01-20
PA8804801A1 (es) 2009-06-23
AU2008328311A1 (en) 2009-05-28
US20100292156A1 (en) 2010-11-18
ZA201003586B (en) 2011-08-31
CL2008003475A1 (es) 2009-03-27
AP2010005265A0 (en) 2010-06-30
HRP20110904T1 (hr) 2011-12-31
KR101585868B1 (ko) 2016-01-22
UA97867C2 (ru) 2012-03-26
ECSP10010153A (es) 2010-06-29
PL2222275T3 (pl) 2012-03-30
WO2009065507A3 (en) 2009-09-03
TN2010000215A1 (en) 2011-11-11
CN101868225A (zh) 2010-10-20
EP2222275B1 (en) 2011-10-19
CN101868225B (zh) 2013-06-12
RS52045B (sr) 2012-04-30
TWI448292B (zh) 2014-08-11
HK1149714A1 (en) 2011-10-14
ITMI20072225A1 (it) 2009-05-24
IL205860A0 (en) 2010-11-30
ES2374861T3 (es) 2012-02-22
MA31913B1 (fr) 2010-12-01
TW200927151A (en) 2009-07-01
US9101627B2 (en) 2015-08-11
EA017626B1 (ru) 2013-01-30
ATE529096T1 (de) 2011-11-15
KR20100096106A (ko) 2010-09-01
JP2011504473A (ja) 2011-02-10
DK2222275T3 (da) 2012-01-02
CR11457A (es) 2010-11-05
PE20091422A1 (es) 2009-10-17
JP5383695B2 (ja) 2014-01-08
BRPI0820402A2 (pt) 2015-05-19
AP2628A (en) 2013-03-26
NZ585514A (en) 2012-01-12
MX2010005484A (es) 2010-06-07
CO6270301A2 (es) 2011-04-20
SI2222275T1 (sl) 2012-01-31
CA2706398C (en) 2016-07-05
CA2706398A1 (en) 2009-05-28
GEP20125602B (en) 2012-08-10

Similar Documents

Publication Publication Date Title
CY1112831T1 (el) Παραγωγα αζαβιρηενυlαμινοβενζοιc acid σαν παραγοντες καταστολης dhodh
CY1115082T1 (el) Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπανιου, παρασκευες και χρησεις αυτων
CY1117476T1 (el) Ανταγωνιστες συμπληρωματων και οι χρησεις αυτων
CY1118221T1 (el) Εκλεκτικοι συνδετες συνδεσης οψινης, συνθεσεις και μεθοδοι χρησης
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
CY1120319T1 (el) Πρωτεϊνες συντηξης και εμβολια συνδυασμου που περιλαμβανουν haemophilus influenzae πρωτεϊνη ε και πιλινη α
IN2012DN02736A (el)
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
CY1111454T1 (el) Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων
CY1110929T1 (el) Παραγωγα πυριδαζινονης ως αγωνιστες υποδοχεων θυρεοειδικης ορμονης
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
BRPI0709581A8 (pt) compostos de bicicloeteroarila como moduladores de px27 e seu uso
CY1111747T1 (el) 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα
CY1113869T1 (el) Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf
CY1117326T1 (el) Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson
CY1118044T1 (el) Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
MY167804A (en) Treatment of degenerative joint disease
CY1112134T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν ανταγωνιστες βραδυκινινης και υαλουρονικο οξυ και χρησεις αυτων
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
CY1115961T1 (el) Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate)
DK1987063T3 (da) Peptider og peptidderivater, fremstilling deraf samt deres anvendelse til fremstilling af en terapeutisk og/eller præventivt aktiv farmaceutisk sammensætning
BRPI0917245A8 (pt) Compostos derivados de isoquinolinona e sua composição farmacêutica